open access publication

Review, 2024

Focusing on earlier diagnosis of Alzheimer's disease

Future Neurology, ISSN 1479-6708, Volume 19, 1, 10.2217/fnl-2023-0024

Contributors

Frederiksen K.S. 0000-0001-5124-4417 (Corresponding author) [1] [2] Arus X.M. [3] Zetterberg H. 0000-0003-3930-4354 [4] [5] [6] [7] [8] Gauthier S. [9] Boada M. 0000-0003-2617-3009 [3] [10] Pytel V. [3] Hahn-Pedersen J.H. [11] Solis Tarazona L.R. [11] Mattke S. [12]

Affiliations

  1. [1] Rigshospitalet
  2. [NORA names: Capital Region of Denmark; Hospital; Denmark; Europe, EU; Nordic; OECD];
  3. [2] University of Copenhagen
  4. [NORA names: KU University of Copenhagen; University; Denmark; Europe, EU; Nordic; OECD];
  5. [3] Universitat Internacional de Catalunya
  6. [NORA names: Spain; Europe, EU; OECD];
  7. [4] Institute of Neurology
  8. [NORA names: United Kingdom; Europe, Non-EU; OECD];
  9. [5] Sahlgrenska Academy
  10. [NORA names: Sweden; Europe, EU; Nordic; OECD];

Abstract

Alzheimer's disease (AD) is considered a continuum, progressing from preclinical disease to mild cognitive impairment (MCI) as an early stage, before reaching clinically apparent dementia. Although it is difficult to assess the potential impairments in performance of patients with MCI due to AD, this condition should be diagnosed as early as possible so that, by means of early interventions, patients can maintain their quality of life longer. Healthcare systems should support primary care physicians in their effort to identify patients with MCI due to AD and refer patients to memory clinics and specialists who can provide a reliable diagnosis and initiate appropriate disease management. This review discusses the benefits of earlier AD diagnosis, along with potential challenges and future directions.

Keywords

AD dementia, Alzheimer disease, Alzheimer's disease, MCI due to AD, amnestic, cognitive disorders, cognitive symptoms, dementia, diagnosis of MCI due to AD, early AD diagnosis

Funders

  • Novo Nordisk

Data Provider: Elsevier